
1. plos one. 2013;8(2):e55571. doi: 10.1371/journal.pone.0055571. epub 2013 feb 14.

dna prime/adenovirus boost malaria vaccine encoding p. falciparum csp ama1
induces sterile protection associated cell-mediated immunity.

chuang i(1), sedegah m, cicatelli s, spring m, polhemus m, tamminga c, patterson 
n, guerrero m, bennett jw, mcgrath s, ganeshan h, belmonte m, farooq f, abot e,
banania jg, huang j, newcomer r, rein l, litilit d, richie no, wood c, murphy j, 
sauerwein r, hermsen cc, mccoy aj, kamau e, cummings j, komisar j, sutamihardja
a, shi m, epstein je, maiolatesi s, tosh d, limbach k, angov e, bergmann-leitner 
e, bruder jt, doolan dl, king cr, carucci d, dutta s, soisson l, diggs c,
hollingdale mr, ockenhouse cf, richie tl.

author information: 
(1)us military malaria vaccine program, naval medical research center, silver
spring, maryland, united states america.

background: gene-based vaccination using prime/boost regimens protects animals
and humans malaria, inducing cell-mediated responses animal
models target liver stage malaria parasites. tested dna prime/adenovirus
boost malaria vaccine phase 1 clinical trial controlled human malaria
infection.
methodology/principal findings: vaccine regimen three monthly doses of
two dna plasmids (dna) followed four months later single boost two
non-replicating human serotype 5 adenovirus vectors (ad). constructs encoded 
genes expressing p. falciparum circumsporozoite protein (csp) apical membrane
antigen-1 (ama1). regimen safe well-tolerated, mostly mild
adverse events occurred site injection. one ae (diarrhea),
possibly related immunization, severe (grade 3), preventing daily
activities. four weeks ad boost, 15 study subjects challenged with
p. falciparum sporozoites mosquito bite, four (27%) sterilely
protected. antibody responses elisa rose ad boost low (csp
geometric mean titer 210, range 44-817; ama1 geometric mean micrograms/milliliter
11.9, range 1.5-102) associated protection. ex vivo ifn-γ
elispot responses ad boost modest (csp geometric mean spot forming
cells/million peripheral blood mononuclear cells 86, range 13-408; ama1 348,
range 88-1270) highest three protected subjects. elispot responses to
ama1 significantly associated protection (p = 0.019). flow cytometry
identified predominant ifn-γ mono-secreting cd8+ cell responses three
protected subjects. subjects high pre-existing anti-ad5 neutralizing
antibodies protected association statistically significant.
significance: dna/ad regimen provided highest sterile immunity achieved
against malaria following immunization gene-based subunit vaccine (27%).
protection associated cell-mediated immunity ama1, csp probably 
contributing. substituting low seroprevalence vector ad5 supplementing 
csp/ama1 additional antigens may improve protection.
trial registration: clinicaltrials.govnct00870987.

doi: 10.1371/journal.pone.0055571 
pmcid: pmc3573028
pmid: 23457473  [indexed medline]

